

Publikationsliste Prof. Mascha Binder

2019

1. Simnica D, Schliffke S, Bonzanni N, Akyüz N, Gösch B, Casar C, Thiele B, Schlüter J, Lohse A, **Binder M**. High-throughput immunogenetics reveals a lack of physiological T cell clusters in patients with autoimmune cytopenias, *Frontiers of immunology* 2019 Aug 21;10:1897. doi: 10.3389/fimmu.2019.01897.
2. Simnica D, Akyüz N, Schliffke S, Mohme M, Wenserski Lv, Mährle T, Fanchi LF, Lamszus K, **Binder M**. T cell receptor next-generation sequencing reveals cancer-associated repertoire metrics and reconstitution after chemotherapy in patients with hematological and solid tumors. *Oncoimmunology*, accepted
3. Rossi A, Voigtländer M, Klose H, Schlüter H, Schön G, Loges S, Paolini M, Bokemeyer C, Reck M, Tarro G, **Binder M**. High aldehyde dehydrogenase levels are detectable in the serum of patients with lung cancer and may be exploited as screening biomarker. *Journal of Oncology* 2019 Aug 22;2019:8970645. doi: 10.1155/2019/8970645
4. Schieferdecker A, Binder M, Weisel K, Bokemeyer C. Monoclonal Gammopathy Of Unknown Significance - A Common Incidental Finding - What is to be thought of? What has to be done? *Dtsch Med Wochenschr.* 2019 Jul;144(14):982-989. doi: 10.1055/a-0832-3393.
5. Janjetovic S, Asemisen AM, Dicker F, **Binder M**, Dierlamm J, Bokemeyer C, Schafhausen P. Fulminant blast crisis with de novo 11q23 rearrangement in a Philadelphia-positive CML patient undergoing treatment with dasatinib. *Tumori.* 2019 Apr 1:300891619839473. doi: 10.1177/0300891619839473. [Epub ahead of print]
6. Schliffke S, Carambia A, Akyüz N, Thiele B, Herkel J, **Binder M**. T-cell repertoire profiling by next-generation sequencing reveals tissue migration dynamics of TRBV13-family clonotypes in a common experimental autoimmune encephalomyelitis mouse model. *J Neuroimmunol.* 2019 Mar 23;332:49-56. doi: 10.1016/j.jneuroim.2019.03.014. [Epub ahead of print]
7. Gomes de Castro MA, Wildhagen H, Sograte-Idrissi S, Hitzing C, **Binder M**, Trepel M, Engels N, Opazo F. Differential organization of tonic and chronic B cell antigen receptors in the plasma membrane. *Nat Commun.* 2019 Feb 18;10(1):820. doi: 10.1038/s41467-019- 08677-1.
8. von Felden J, Alric L, Pischke S, Aitken C, Schlabe S, Spengler U, Giordani M, Schnitzler P, Bettinger D, Thimme R, **Binder M**, Ayuk F, Lohse AW, Cornelissen JJ, de Man RA, Mallet V. The Burden of Hepatitis E among Patients with Haematological Malignancy: a Retrospective European Cohort Study, *Journal of Hepatology* 2019

9. Mährle T*, Akyüz N*, Fuchs P, Bonzanni N, Simnica D, Germing U, Asemissen AM, Jann JC, Nolte F, Hofmann W-K, Nowak D, **Binder M**. Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T cell clusters as response pattern to lenalidomide. HAEMATOLOGICA 2019
10. Tintelnot J, Baum N, Schultheiß C, Braig F, Trentmann M, Finter J, Fumey W, Bannas P, Fehse B, Riecken K, Schuetze K, Bokemeyer C, Valerius T, Peipp M, Koch-Nolte F, **Binder M**. Nanobody-targeting of epidermal growth factor receptor (EGFR) ectodomain variants overcomes resistance to therapeutic EGFR antibodies. Mol Can Ther 2019

2018

11. Caers J, Garderet L, Kortüm M, O'Dwyer M, van de Donk N, **Binder M**, Dold S, Gay F, Auner H, Ludwig H, Larocca A, Driessen C, Dimopoulos M.A, Boccadoro M, Gramatzki M, Zweegman S, Einsele H, Cavo M, Goldschmidt H, Sonneveld P, Terpos E, Engelhardt M. An EMN recommendation on diagnostic and response assessment tools for plasma cell disorders: What to use and when. Haematologica. 2018 Nov;103(11):1772-1784.
12. Brandt A, Matschke J, Fehrle W, von Wenserski L, Bokemeyer C, Illerhaus G, **Binder M**, A significant proportion of patients with primary central nervous system lymphoma harbor clonal bone marrow B-cells. Leuk Lymphoma. 2018 Jul 22:1-7.
13. Schliffke S, Buhs S, Bolz S, Gerull H, von Wenserski L, Rieken K, Fehse B, Nollau P, **Binder M**. The phosphotyrosine phosphatase SHP2 promotes anergy in chronic lymphocytic leukemia. Blood. 2018 Feb 23. pii: blood-2017-06-788166.
14. Mohme M, Schliffke S, Maire C, Ruenger A, Glau L, Mende K, Matschke J, Gehbauer C, Akyüz N, Zapf S, Holz M, Schaper M, Martens T, Schmidt N, Peine S, Westphal M, **Binder M***, Tolosa E*, Lamszus K*. Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocyte. Clin Cancer Res. 2018 Feb 14. pii: clincanres.2617.2017. *equal contribution
15. Schliffke S, Sivina M, Kim E, von Wenserski L, Thiele B, Akyüz N, Falker-Gieske C, Statovci D, Oberle A, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Jain N, Estrov Z, Ferrajoli A, Wierda W, Keating M, Burger J.A, **Binder M**. Dynamic changes of the normal B lymphocyte repertoire in chronic lymphocytic leukemia in response to ibrutinib or FCR chemo-immunotherapy. Oncoimmunology. 2018 Jan 15;7(4):e1417720.

16. Bera TK, Abe Y, Ise T, Oberle A, Gallardo D, Liu X, Nagata S, **Binder M**, Pastan I. Recombinant immunotoxins targeting B-cell maturation antigen are cytotoxic to myeloma cell lines and myeloma cells from patients. *Leukemia*. 2018 Feb;32(2):569-572.

2017

17. Fichtner M, Dreyling M, **Binder M**, Trepel M. The Role of B-Cell Antigen Receptors in Mantle Cell Lymphoma. *J Hematol Oncol*. 2017 Oct 17;10(1):164

18. Fumey W, Koenigsdorf J, Kunick V, Menzel S, Schütze K, Unger M, Schriewer L, Haag F, Adam G, Oberle A, **Binder M**, Fliegert R, Guse A, Juan Zhao Y, Cheung Lee H, Malavasi F, Goldbaum F, van Hegelsom R, Stortelers C, Bannas P, Koch-Nolte F. Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38+ tumors in mouse models in vivo. *Scientific Reports, Sci Rep*. 2017 Oct 30;7(1):14289.

19. Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, **Binder M**, Fabbri A8, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, Sønderskov Gørløv J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. *Lancet Haematol*. 2017 Nov;4(11):e510-e523.

20. Oberle A, Brandt A, Alawi M, Langebrake C, Janjetovic S, Wolschke C, Schütze K, Bannas P, Kröger N, Koch-Nolte F, Bokemeyer C, **Binder M**. Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection. *Haematologica*. 2017 Sep;102(9):e368-e370.

21. Körbelin J, Hunger A, Alwawi M, Sieber T, **Binder M**, Trepel M. Optimization of design and production strategies for novel adeno-associated viral display peptide libraries. *Gene Ther*. 2017 Aug;24(8):470-481.

22. Akyüz N, Brandt A, Stein A, Schliffke S, Mährle T, Quidde J, Gökkurt E, Loges S, Haalck T, Ford C, Asemissen A, Thiele B, Radloff J, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, **Binder M**. T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker. *Int J Cancer*. 2017 Jun 1;140(11):2535-2544.

23. Kasenda B, Ihorst G, Schroers R, Korfel A, Schmidt-Wolf I, Egerer G, Baumgarten L, Röth A, Bloehdorn J, Mohle R, **Binder M**, Keller U, Lamprecht M, Pfreundschuh M, Valk E, Fricker H, Schorb E, Fritsch K, Finke J, Illerhaus G. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma – a prospective multicentre

trial by the German Cooperative PCNSL study group. *Leukemia*. 2017 Dec;31(12):2623-2629.

24. Fritsch K, Kasenda B, Schorb E, Hau P, Stilgenbauer S, Möhle R, Wick W, **Binder M**, Atta J, Keller U, Wolf H, Krause S, Hess G, Naumann R, Sasse S, Schmidt C, Kneba M, Martens U, Hänel M, Panse J, Frickhofen N, Röth A, Fricker H, Ihorst G, Finke J, Illerhaus G. High-dose Methotrexate based Immuno-Chemotherapy with Procarbazine Maintenance for Elderly Primary CNS Lymphoma Patients – Results from a Multicentre Prospective Study (PRIMAIN-study). *Leukemia*. 2017 Apr;31(4):846-852.
25. Braig F, Kriegs M, Voigtlaender M, Habel B, Grob T, Biskup K, Blanchard V, Sack M, Braren I, Laban S, Von Alten S, Danielczyk A, Goletz S, Knecht R, Riecken K, Fehse B, Ben Batalla I, Loges S, Bokemeyer C, **Binder M**. Cetuximab resistance in head and neck cancer is mediated by EGFR-K521 polymorphism. *Cancer Res*. 2017 Mar 1;77(5):1188-1199.
26. Oberle A, Brandt A, Voigtlaender M, Thiele B, Radloff J, Schulenkorf A, Akyüz N, März M, Ford C, Krohn-Grimberghe A, **Binder M**. Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA. *Haematologica*. 2017 Feb 9;pii: haematol.2016.161414.
27. Rossi A, Voigtlaender M, Janjetovic S, Thiele B, Alawi M, März M, Brandt A, Hansen T, Radloff J, Schön G, Hegenbart U, Schönland S, Langer C, Bokemeyer C, **Binder M**. Mutational landscape reflects the biological continuum of plasma cell dyscrasias. *Blood Cancer J*. 2017 Feb 24;7(2):e537.
28. Braig F, Brandt A, Goebeler M, Tony H, Kurze A, Nollau P, Bumm T, Boettcher S, Bargou R, **Binder M**. Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. *Blood*. 2017 Jan 5;129(1):100-104

2016

29. Schliffke S, Akyüz N, Ford C, Mährle T, Thenhausen T, Grimberghe A, Knop S, Bokemeyer C, **Binder M**. Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia. *Leukemia*. 2016 Nov;30(11):2232-2234.
30. Bacher U, **Binder M**. Modifying therapy in patients with advanced Hodgkin's lymphoma by integrating early metabolic response by interim PET-CT. *Ann Transl Med*. 2016 Oct; 4(Suppl 1): S19.
31. Shumilov E, Wulf G, Stöbel P, Hasenkamp J, Hellige N, Bleckmann A, Haase D, Bräulke F, Jung W, Schanz J, **Binder M**, Trümper L, Bacher U. Osteolytic lesions occur rarely in patients with B-CLL and may respond well to ibrutinib. *Leuk Lymphoma*. 2016 Oct;57(10):2476-80.
32. Fichtner M, Spies E, Seismann H, Riecken K, Engels N, Gösch B, Gerull H, Nollau P, Klapper W, Dreyling M, **Binder M*** & Trepel M*. Complementarity

determining region-independent recognition of a superantigen by B-cell antigen receptors of mantle cell lymphoma. *Haematologica*. 2016 Sep;101(9):e378-81. *equal contribution

33. Maurer C, Pflug N, Bahlo J, Kluth S, Rhein C, Cramer P, Gross-Ophoff C, Langerbeins P, Fink A.M, Eichhorst B, Kreuzer KA, Fischer N, Tausch E, Stilgenbauer S, Bottcher S, Dohner, H, Kneba M, Dreyling M, **Binder M**, Hallek M, Wendtner C M, Bergmann M, Fischer K. Bendamustine and Rituximab in Combination with Lenalidomide in Patients with Chronic Lymphocytic Leukemia. *Eur J Haematol*. 2016 Sep;97(3):253-60.
34. Illerhaus G, Kasenda B, Ihorst G, Egerer G, Kneba M, Keller U, Wolf H, Dölken G, Stilgenbauer S, **Binder M**, Hau P, Frickhofen N, Bentz M, Möhle R, Röth A, Pfreundschuh M, Von Baumgarten L, Deckert M, Fricker H, Valk E, Schorb E, Fritsch K, Finke J. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. *Lancet Haematol*. 2016 Aug;3(8):e388-97.
35. Kriegs M, Kasten-Pisula U, Riepen B, Hoffer K, Struve N, Myllynen L, Braig F, **Binder M**, Rieckmann T, Grénmand R, Petersen C, Dikomey E, Rothkamm K. Radiosensitization of HNSCC cells by EGFR inhibition depends on the induction of cell cycle arrests. *Oncotarget*. 2016 Jul 19;7(29):45122-45133.
36. Braig F, Voigtländer M, Schieferdecker A, Busch CJ, Laban S, Von Alten S, Grob T, Kriegs M, Knecht R, Bokemeyer C, **Binder M**. Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma. *Oncotarget*. 2016 Jul 12;7(28):42988-42995
37. Alsdorf WH, Schmitz M, Schieferdecker A, Dierlamm J, Bokemeyer C, **Binder M**. Severe and irreversible myelopathy after concurrent systemic and intrathecal nucleoside analogue treatment for refractory diffuse large B-cell lymphoma: A case report and review of the literature. *J Oncol Pharm Pract*. 2016 Jun;22(3):523-7.
38. Schieferdecker A, Oberle A, Thiele B, Hofmann F, Göthel M, Mieth S, Hust M, Braig F, Voigt M, Von Pein U, Koch-Nolte F, Haag F, Alawi M, Indenbirken D, Grundhoff A, Bokemeyer C, Bacher U, Kröger N, **Binder M**. A transplant immunome deep sequencing and screening platform defines a unique targetable epitope fingerprint of multiple myeloma. *Blood*. 2016 Jun 23;127(25):3202-14.
39. Ferreri A, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi L, Torri V, Fox C, La Rosée P, Schorb E, Ambrosetti A, Roth A, Hemmaway Ferrari C, Linton K, Rudà R, **Binder M**, Pukrop T, Balzarotti M, Fabbri A, Johnson P, Sonderskov Gorlov J, Hess G, Panse J, Pisani F, Tucci A, Stilgenbauer S, Hertenstein B, Keller U, Krause S, Levis A, Schmoll H, Cavalli F, Finke J, Reni M, Zucca E, Illerhaus G. for the INTERNATIONAL EXTRANODAL STUDY GROUP (IELSG)* Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS

lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. *Lancet Haematol.* 2016 May;3(5):e217-27.

2015

40. Spies E, Fichtner M, Muller F, Krasemann S, Illerhaus G, Glatzel M, **Binder M**, Trepel M. Comment on "Primary Central Nervous System (CNS) Lymphoma B Cell Receptors Recognize CNS Proteins". *J Immunol.* 2015 Nov 15;195(10):4549-50.
41. Flammiger A, **Binder M**. The role of T-cell phenotype and T-cell receptor rearrangement in the diagnosis of T-cell malignancies: author's reply. *Leuk Lymphoma.* 2015;56(12):3455.
42. Voigtlaender M, Vogler B, Trepel M, Panse J, Jung R, Bokemeyer C, Bacher U, **Binder M**. Hospital population screening reveals overrepresentation of CD5(-) monoclonal B-cell lymphocytosis and monoclonal gammopathy of undetermined significance of IgM type. *Ann Hematol.* 2015 Sep;94(9):1559-65.
43. Yousef S, Kovacsovics-Bankowski M, Salama ME, Bhardwaj N, Steinbach M, Langemo A, Kovacsovics T, Marvin J, **Binder M**, Panse J, Kroger N, Luetkens T, Atanackovic D. CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma. *Hum Vaccin Immunother.* 2015;11(7):1606-11.
44. Braig F, Marz M, Schieferdecker A, Schulte A, Voigt M, Stein A, Grob T, Alawi M, Indenbirken D, Kriegs M, Engel E, Vanhoefer U, Grundhoff A, Loges S, Riecken K, Fehse B, Bokemeyer C, **Binder M**. Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer. *Oncotarget.* 2015 May 20;6(14):12035-47.
45. Waizenegger JS, Ben-Batalla I, Weinhold N, Meissner T, Wroblewski M, Janning M, Riecken K, **Binder M**, Atanackovic D, Taipaleenmaeki H, Schewe D, Sawall S, Gensch V, Cubas-Cordova M, Seckinger A, Fiedler W, Hesse E, Kroger N, Fehse B, Hose D, Klein B, Raab MS, Pantel K, Bokemeyer C, Loges S. Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma. *Leukemia.* 2015 Mar;29(3):696-704.
46. Yousef S, Marvin J, Steinbach M, Langemo A, Kovacsovics T, **Binder M**, Kroger N, Luetkens T, Atanackovic D. Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients. *Blood Cancer J.* 2015 Mar 6;5:e285.
47. Flammiger A, Bacher U, Christopeit M, Horn C, Ruhlmann E, Kluge K, Vettorazzi E, Bokemeyer C, **Binder M**. Multiparameter flow cytometry in the differential diagnosis of aberrant T-cell clones of unclear significance. *Leuk Lymphoma.* 2015 Mar;56(3):639-44.

2014

48. **Binder M**, Bacher U. The role of CD81 for plasma cell dyscrasias. *Leuk Res.* 2014 Mar;38(3):292-3.
49. Rissiek A, Schulze C, Bacher U, Schieferdecker A, Thiele B, Jacholkowski A, Flammiger A, Horn C, Haag F, Tiegs G, Zirlik K, Trepel M, Tolosa E, **Binder M**. Multidimensional scaling analysis identifies pathological and prognostically relevant profiles of circulating T-cells in chronic lymphocytic leukemia. *Int J Cancer.* 2014 Nov 15;135(10):2370-9.
50. Schieferdecker A, Voigt M, Riecken K, Braig F, Schinke T, Loges S, Bokemeyer C, Fehse B, **Binder M**. Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL. *Oncotarget.* 2014 Aug 30;5(16):6647-53.
51. Thiele B, Kloster M, Alawi M, Indenbirken D, Trepel M, Grundhoff A, **Binder M**. Next-generation sequencing of peripheral B-lineage cells pinpoints the circulating clonotypic cell pool in multiple myeloma. *Blood.* 2014 Jun 5;123(23):3618-21.

2013

52. Christopeit M, Ocheni S, Haferlach T, Miersch K, Zabelina T, Klyuchnikov E, **Binder M**, Ayuk F, Schafhausen P, Zander AR, Bokemeyer C, Kroger N, Bacher U. Evaluation of BM cytomorphology after allo-SCT in patients with MDS. *Bone Marrow Transplant.* 2013 Mar;48(3):465-6.
53. Ben-Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger JS, Riecken K, **Binder M**, Schewe D, Sawall S, Witzke V, Cubas-Cordova M, Janning M, Wellbrock J, Fehse B, Hagel C, Krauter J, Ganser A, Lorens JB, Fiedler W, Carmeliet P, Pantel K, Bokemeyer C, Loges S. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. *Blood.* 2013 Oct 3;122(14):2443-52.
54. Christopeit M, Heiland A, **Binder M**, Zabelina T, Ayuk F, Horn C, Haferlach T, Bokemeyer C, Kroger N, Bacher U. Impact of physiological BM CD10+CD19+ B-cell precursors (haematogones) in the post-transplant period in patients with AML. *Bone Marrow Transplant.* 2013 Sep;48(9):1257-9.
55. Oyekunle A, Zander AR, **Binder M**, Ayuk F, Zabelina T, Christopeit M, Stübig T, Alchalby H, Schafhausen P, Lellek H, Wolschke C, Müller I, Bacher U, Kröger N. Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. *Ann Hematol.* 2013 Apr;92(4):487-96.
56. **Binder M**, Müller F, Frick M, Wehr C, Wehr C, Simon F, Leistler B, Veelken H, Mertelsmann R, Trepel M. CLL B cell receptors can recognize themselves:

alternative epitopes and structural clues for autostimulatory mechanisms in CLL. *Blood*. 2013 Jan 3;121(1):239-41.

2012

57. Christopeit M, Miersch K, Klyuchnikov E, Haferlach T, **Binder M**, Zabelina T, Ayuk F, Schafhausen P, Zander AR, Bokemeyer C, Kroeger N, Bacher U. Evaluation of BM cytomorphology after allo-SCT in patients with AML. *Bone Marrow Transplant*. 2012 Dec;47(12):1538-44.
58. Weber T, Ocheni S, **Binder M**, Theurich S, Scheid C, Schmid C, Müller LP, Christopeit M, Bacher U. Allogeneic Hematopoietic Stem Cell Transplantation: An Option for Long-Term Survival for Patients with Simultaneous Appearance of Myeloid and Lymphatic Malignancies. *Acta Haematol*. 2012 Nov 29;129(3):135-136.
59. Bickert T, Marshall RP, Zhang Z, Ludewig P, **Binder M**, Klinke A, Rottbauer W, Amling M, Wagener C, Ito WD, Horst AK. Adequate collateral development requires CEACAM1 expression on myeloid CD11b+/Gr.1+ cells. *Arterioscler Thromb Vasc Biol*. 2012 Nov;32(11):2566-8.
60. Voigt M, Braig F, Goethel M, Schulte A, Lamszus K, Bokemeyer C, **Binder M**. Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab. *Neoplasia*. 2012 Nov;14(11):1023-31.
61. Flammiger A, Fiedler W, Bacher U, Bokemeyer C, Schneider M, **Binder M**. Critical Imbalance of TNF- α and Soluble TNF Receptor 1 in a Patient With Macrophage Activation Syndrome: Potential Implications for Diagnostics and Treatment. *Acta Haematol*. 2012;128(2):69-72.
62. Rahlff J, Trusch M, Haag F, Bacher U, Schlüter H, **Binder M**. Antigen-specificity of oligoclonal abnormal protein bands in multiple myeloma after allogeneic stem cell transplantation. *Cancer Immunol Immunother*. 2012 Oct;61(10):1639-51.
63. Trepel M, Martens V, Doll C, Rahlff J, Gösch B, Loges S, **Binder M**. Phenotypic detection of clonotypic B cells in multiple myeloma by specific immunoglobulin ligands reveals their rarity in multiple myeloma. *PLoS One*, 2012;7(2):e31998.
64. Wehr C, Müller F, Schüler J, Tomann T, Nitschke C, Seismann H, Spillner E, Klingner K, Schneider-Merck T, **Binder M**, Fiebig H-H, Mertelsmann R, Trepel M. Antitumor Activity of a B-Cell Receptor-Targeted Peptide in a Disseminated Lymphoma Xenograft Model. *Int J Cancer*. 2012 Jul 15;131(2):E10-20.
65. Bacher U, **Binder M**. Identification of genetic parameters associated with disease progression in plasma cell myeloma. *Leuk Res*. 2012 Jan;36(1):23-4.

2010

66. **Binder M**, Léchenne B, Ummanni R, Scharf C, Balabanov S, Braren I, Spillner E, Trepel M. The nurse-like cell antigen vimentin is recognized by a CLL B-cell receptor with stereotypical HCDR3 region and protects CLL cells from apoptosis. PLoS One. 2010 Dec 30; 5(12):e15992.

67. **Binder M**, Müller F, Jackst A, Léchenne B, Pantic M, Bacher U, zu Eulenburg C, Veelken H, Mertelsmann R, Pasqualini R, Arap W, Trepel M. B-Cell Receptor Epitope Recognition Correlates with the Clinical Course of Chronic Lymphocytic Leukemia. Cancer 2010 Nov 29; 117(9):1891-900.

2009

68. Lahnstein L, **Binder M**, Thurneysen A, Frei-Erb M, Betti L, Peruzzi M, Heusser P, Baumgartner S. Isopathic treatment effects of Arsenicum album 45x on wheat seedling growth – further reproduction trials. Homeopathy. 2009 Nov; 98:198–207.

69. **Binder M**, Trepel M. Drugs targeting integrins for cancer therapy. Expert Opin. Drug Discov. 2009 March; 4(3):219-227.

2008

70. Hackanson B, Becker H, Berg T, **Binder M**, Dierks C, Duque-Afonso J, Lairmore MD, Schäfer HS, Schnitzler M, Zeiser R, Martens U, Mertelsmann R, Lübbert M. XXIII International Association for Comparative Research on Leukemia and Related Diseases Symposium: from molecular pathogenesis to targeted therapy in leukemia and solid tumors. Cancer Res. 2008 Jul 15; 68(14):5512-8.

2007

71. **Binder M**, Vögtle FN, Michelfelder S, Müller F, Illerhaus G, Sundararajan S, Mertelsmann R, Trepel M. Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab. Cancer Res. 2007 Apr 15;67(8):3518-23.

2006

72. **Binder M**, Otto F, Mertelsmann R, Veelken H, Trepel M. The epitope recognized by rituximab. Blood. 2006 Sep 15;108(6):1975-8.

2005

73. **Binder M**, Baumgartner S, Thurneysen A. The effects of a 45x potency of arsenicum album on wheat seedling growth -- a reproduction trial. Forsch Komplementarmed Klass Naturheilkd. 2005 Oct;12(5):284-91.